PCM
KNTE

Prelude Capital Management’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Prelude Capital Management’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-23,014
Closed -$54.5K – 1573
2023
Q4 		$54.5K Sell
23,014
-9,295
-29% -$16.5K ﹤0.01% 1068
2023
Q3 		$45.2K Buy
32,309
+3,555
+12% +$8.54K ﹤0.01% 1052
2023
Q2 		$87.1K Buy
+28,754
New +$111K 0.01% 942

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prelude Capital Management's KNTE Position: Q1 2024 in Review

Prelude Capital Management sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q1 2024, closing a stake of 23,014 shares — an estimated $54.5K sold.

Prelude Capital Management first reported a position in KNTE in Q2 2023 and held it in 3 quarters. The position peaked at $87.1K in Q2 2023. 56 funds tracked by Wall St. Rank hold KNTE as of Q1 2024.

  • Prelude Capital Management reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 23,014 Kinnate Biopharma Inc. Common Stock shares in Q1 2024, an estimated $54.5K.
  • Prelude Capital Management first reported a position in Kinnate Biopharma Inc. Common Stock in Q2 2023 and held it in 3 quarters.
  • Prelude Capital Management's Kinnate Biopharma Inc. Common Stock position peaked at $87.1K in Q2 2023.
  • 56 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.